FindTrial
Sign In

AZD3470

DRUG3 trials

Sponsors

Astrazeneca AB, AstraZeneca

Conditions

AITLALCLAdvanced Solid Tumors That Are MTAP DeficientAdvanced/metastatic solid tumors that are MTAP deficient.Hodgkin LymphomaLymphomaNon-Hodgkin LymphomaPTCL-NOS

Phase 1

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
RecruitingNCT06130553
AstraZenecaAdvanced Solid Tumors That Are MTAP Deficient
Start: 2024-01-18End: 2028-12-04Target: 334Updated: 2026-05-11
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
RecruitingNCT06137144
AstraZenecaAITL, ALCL, Hodgkin Lymphoma +4
Start: 2024-01-23End: 2029-04-30Target: 161Updated: 2026-05-19
PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours That are MTAP Deficient
RecruitingCTIS2023-506757-38-00
Astrazeneca ABAdvanced/metastatic solid tumors that are MTAP deficient.
Start: 2024-11-27Target: 40Updated: 2025-09-02

Related Papers

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
Blood2024-11-053 citations
Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies
Blood2024-11-051 citations
PRIMROSE: A modular phase 1/2a study of AZD3470, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP deficient advanced solid tumors.
Journal of Clinical Oncology2024-06-019 citations
Abstract LB008: Integrative dynamic MultiOMICs analysis identifies cell cycle and DNA damage response phenotypes as downstream consequences of using the PRMT5 inhibitor AZD3470
Cancer Research2024-04-053 citations